产品名称	VCaP人前列腺癌细胞
货号	ZQ0353
产品介绍	VCaP(前列腺Vertebral-Cancer)细胞株是研究前列腺癌的重要模型,源于人类前列腺癌的脊椎转移，它在体外和体内均对雄激素敏感。它的建立是为了提供一个相关的体外模型，用于研究前列腺癌的生物学及其转移过程，特别是关注该疾病的激素难治性阶段。VCaP细胞以高水平表达前列腺特异性抗原(PSA)和雄激素受体(AR)而闻名，这使得它们与雄激素受体信号通路和抗雄激素治疗耐药机制的研究高度相关。 VCaP细胞也被广泛用于遗传学研究，因为它们含有TMPRSS2-ERG基因融合，这是一种常见的染色体易位，在大约50%的前列腺癌病例中发现。这种特殊的基因改变是重要的，因为它被认为在前列腺癌的进展中起着至关重要的作用。因此，这些细胞是研究前列腺癌的分子基础和开发针对TMPRSS2-ERG及其相关途径的新治疗策略的绝佳工具。此外，VCaP细胞在体外表现出强大的生长能力，并且在免疫缺陷小鼠体内异种移植时可以形成肿瘤，为新的抗癌药物的临床前研究提供了一个有用的系统。 总的来说，VCaP细胞系是分子和药理学研究的重要资源，对了解前列腺癌生物学和评估新的治疗药物有重要贡献。它的特点，包括激素反应性、基因融合表达和转移性起源，使其特别适合于晚期前列腺癌的研究，特别是在与雄激素独立性和转移性疾病进展相关的领域。 需用Gibco TrypLE Express进行消化。预定此细胞需至少提前两周。 特别注意： （1）VCaP细胞长得较慢，传代后细胞需要 48 小时贴壁，细胞需在48小时后换液操作。刚复苏后长到50%融合度需要1-2周，并且有时会出现漂浮的细胞团块和细胞碎片，这些属于正常现象。建议按照我们推荐的接种密度传代和维持培养。 （2）如果观察有小细胞团边缘透亮显示细胞没有完全贴 壁。正常细胞形态呈块状聚团生长。Vcap细胞贴壁后呈现许多小的紧密连接的细胞团块以及单细胞。如果传代或换液时有许多漂浮的细胞，请收集并离心，这些细胞可以继续培养。
种属	人
性别/年龄	男/59岁
组织	前列腺；来源于转移部位:脊椎转移
疾病	癌症
细胞类型	上皮细胞
形态学	上皮的
生长方式	贴壁
倍增时间	大约51~220小时
培养基和添加剂	DMEM高糖（品牌：中乔新舟 货号：ZQ-100）+10%胎牛血清（中乔新舟 货号：ZQ0500）+1%P/S（中乔新舟  货号：CSP006）
推荐完全培养基货号	ZM0353
生物安全等级	BSL-2
STR位点信息	Amelogenin: X,Y CSF1PO: 10,12 D13S317: 11,12 D16S539: 9 D5S818: 12 D7S820: 9,12 TH01: 9.3 TPOX: 8,11 vWA: 18,19
培养条件	95%空气，5%二氧化碳；37℃
抗原表达/受体表达	***
基因表达	***
保藏机构	ATCC; CRL-2876 ECACC; 06020201
供应限制	仅供科研使用

货号	ZQ0353
发货规格	活细胞：T25培养瓶*1瓶或者1ml 冻存管*1支（细胞量约为5 x 10^5 cells/vial）二选一
发货形式	活细胞：常温运输；冻存管：干冰运输
储存温度	活细胞：培养箱；冻存管：液氮罐
产地	中国
供应限制	仅供科研使用

PubMed=11317522
Korenchuk S., Lehr J.E., McLean L., Lee Y.-G., Whitney S., Vessella R.L., Lin D.L., Pienta K.J.
VCaP, a cell-based model system of human prostate cancer.
In Vivo 15:163-168(2001)

PubMed=14518029; DOI=10.1002/pros.10290
van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.
Molecular characterization of human prostate carcinoma cell lines.
Prostate 57:205-225(2003)

PubMed=14518030; DOI=10.1002/pros.10291
van Bokhoven A., Caires A., Di Maria M., Schulte A.P., Lucia M.S., Nordeen S.K., Miller G.J., Varella-Garcia M.
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines.
Prostate 57:226-244(2003)

CLPUB00698

van Bokhoven A.
Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.
Thesis PhD (2004), Katholieke Universiteit Nijmegen, Netherlands

PubMed=21698104; DOI=10.1371/journal.pone.0020874
Sfanos K.S., Aloia A.L., Hicks J.L., Esopi D.M., Steranka J.P., Shao W., Sanchez-Martinez S., Yegnasubramanian S., Burns K.H., Rein A., De Marzo A.M.
Identification of replication competent murine gammaretroviruses in commonly used prostate cancer cell lines.
PLoS ONE 6:E20874-E20874(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23447416; DOI=10.1002/path.4186
Weier C., Haffner M.C., Mosbruger T.L., Esopi D.M., Hicks J.L., Zheng Q.-Z., Fedor H., Isaacs W.B., De Marzo A.M., Nelson W.G., Yegnasubramanian S.
Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer.
J. Pathol. 230:174-183(2013)

PubMed=23615946; DOI=10.1007/s00439-013-1308-1
Teles Alves I., Hiltemann S., Hartjes T., van der Spek P.J., Stubbs A., Trapman J., Jenster G.
Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line.
Hum. Genet. 132:709-713(2013)

PubMed=23671654; DOI=10.1371/journal.pone.0063056
Lu Y.-H., Soong T.D., Elemento O.
A novel approach for characterizing microsatellite instability in cancer cells.
PLoS ONE 8:E63056-E63056(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G.-Z., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E.T., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H.-B., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Meyers B.H., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28145883; DOI=10.18632/oncotarget.14850
Nouri M., Caradec J., Lubik A.A., Li N., Hollier B.G., Takhar M., Altimirano-Dimas M., Chen M.-Q., Roshan-Moniri M., Butler M., Lehman M., Bishop J., Truong S., Huang S.-C., Cochrane D., Cox M., Collins C., Gleave M.E., Erho N., Alshalafa M., Davicioni E., Nelson C., Gregory-Evans S., Karnes R.J., Jenkins R.B., Klein E.A., Buttyan R.
Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance.
Oncotarget 8:18949-18967(2017)

PubMed=30305041; DOI=10.1186/s12885-018-4848-x
Jividen K., Kedzierska K.Z., Yang C.-S., Szlachta K., Ratan A., Paschal B.M.
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer.
BMC Cancer 18:960.1-960.20(2018)

PubMed=30244336; DOI=10.1007/s00345-018-2501-6
Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F.
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
World J. Urol. 37:1117-1126(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574.1-3574.11(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

PubMed=34402095; DOI=10.1002/pros.24210
Haffner M.C., Bhamidipati A., Tsai H.K., Esopi D.M., Vaghasia A.M., Low J.-Y., Patel R.A., Guner G., Pham M.-T., Castagna N., Hicks J.L., Wyhs N., Aebersold R., De Marzo A.M., Nelson W.G., Guo T.-N., Yegnasubramanian S.
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
Prostate 81:1159-1171(2021)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)